Program
Topotecan
Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.
Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.
Drug pageTopotecan: every studyMany companies study it; this page follows only the 33 they lead. All 251 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 180 open or running | phase 3since Aug 14, 2002 | Nov 2, 1999 | none ahead |
| Bristol-Myers Squibbits history only | 20 open or running | phase 2since Sep 10, 2005 | Sep 10, 2005 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Advenchen Laboratoriesits history only | 11 open or running | phase 3since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Ascenta Therapeuticsits history only | 10 open or running | phase 2since Nov 7, 2006 | Nov 7, 2006 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 2since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| BioNTechits history only | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 2since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| Gilead Sciencesits history only | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 3since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 17, 2022 | Jun 17, 2022 | none ahead |
| Pfizer | 10 open or running | phase 2since Oct 9, 2018 | Oct 9, 2018 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 3since Jul 8, 2024 | Jul 8, 2024 | Dec 2026phase 3 · NCT06500026 |
| SynerGene Therapeuticsits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
Also a collaborator on its studies: Eisai, Baili-Bio (Chengdu) Pharmaceutical and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2018First study: phase 2 study in Sarcoma, EwingFirst studyNCT03709680 · 128 enrolled · United States, Brazil, Canada and more
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| irinotecan sucrosofaterule | CSPC Pharmaceutical Group | phase 3 | 20 |
Studies
The one study Pfizer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more | 2 | Completed | Aug 26, 2024 | 128 |
How it is read
Names in the registry
- “Topotecan”, 15 entries
- “topotecan”, 11 entries
- “topotecan hydrochloride”, 2 entries
- “Topotecan/Docetaxel combination”, 1 entry
- “Topotecan (Chemotherapy)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Ovarian Neoplasms, 4 studies
- Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.